3:46 PM
 | 
Feb 12, 2019
 |  BC Extra  |  Politics & Policy

Rubio report outlines Chinese threat to U.S. biotech industry

Biotech opportunities for foreign companies doing business in China may be short-lived as the country builds its domestic biosimilars industry, according to a report released Tuesday by Sen. Marco Rubio (R-Fla.).

The report, "Made in China 2025 and the Future of American Industry," was issued through the U.S. Senate Small Business and Entrepreneurship Committee, which Rubio chairs.

According to the...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >